KEYNOTE-407
Regimen
- Experimental
- pembrolizumab + carbo + (nab-)paclitaxel
- Control
- placebo + carbo + (nab-)paclitaxel
Population
1L advanced squamous NSCLC
Key finding
mOS 15.9 vs 11.3 mo, HR 0.64 (0.49-0.85); SoC for 1L squamous NSCLC
Source: PMID 30280635
Timeline
- Enrollment start: 2016-06-09 📎
Guideline citations
- NCCN NSCLC Version 5.2026 (p.183)
- CSCO NSCLC 2025 ⚠️ OCR source